-

KARL STORZ is First to Market with Alexa in the Operating Room

Voice-activated control in the surgical suite is designed to increase efficiency and patient focus.

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ, a leader in operating room technology, has announced a first-to-market move to bring Amazon Alexa to the operating room. Already well established in healthcare as a HIPAA-compliant voice assistant, Alexa Smart Properties will now be available in KARL STORZ integrated operating rooms to help perform a variety of tasks to enhance and streamline surgical workflow.

With the increasing administrative burden on clinical teams to operate equipment and document procedures, the introduction of a voice assistant is an important step toward allowing them to refocus on patient care.

Without having to touch any equipment, the surgical team will now be able to access case setup information, adjust surgical visualization, contact other staff members, and more, from anywhere in the operating room. This will enable unprecedented control for surgeons and team members who are scrubbed in, without sacrificing sterility.

“This partnership with Amazon brings us one step closer to a touchless operating room, where the technology works for the clinical team—not the other way around,” said Christy Gaudet, VP of Surgical Sales & Marketing at KARL STORZ United States.

The technology will be available as an extension of the CollaboratOR, an interactive ecosystem for the KARL STORZ integrated operating room.

The KARL STORZ Alexa-enabled operating room is available for U.S. deployment immediately.

About KARL STORZ

KARL STORZ is an innovative leader in endoscopic technology and surgical imaging solutions across virtually all surgical specialties. Its integrated operating room solutions are designed to enhance collaboration to improve clinical efficiency and outcomes inside the hospital and other sites of care. With subsidiaries around the world, KARL STORZ is a family-owned company based in Tuttlingen, Germany, that designs, engineers, manufactures, and markets all its products with an emphasis on visionary design, precision craftsmanship, and clinical effectiveness. For more information, visit www.karlstorz.com.

Contacts

Susan Mancia
Marketing Communications
KARL STORZ United States
(562) 841-1515

KARL STORZ


Release Versions

Contacts

Susan Mancia
Marketing Communications
KARL STORZ United States
(562) 841-1515

Social Media Profiles
More News From KARL STORZ

ADDING MULTIMEDIA KARL STORZ Announces FDA Clearance for ENDOFLATOR + Insufflator and Smoke Evacuation System

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ, a global leader in minimally invasive surgical technology, is proud to announce it has received U.S. Food and Drug Administration (FDA) clearance for the ENDOFLATOR™ +. ENDOFLATOR + is the next-generation insufflator with integrated surgical smoke evacuation system designed to meet the evolving needs of modern operating rooms. Using carbon dioxide gas, an insufflator establishes and maintains a stable working cavity within the body during laparos...

KARL STORZ Unifies Canada, US, and Veterinary Organizations to Form North America Region Led by Sonal Matai

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ, a family-owned medical technology company headquartered in Tuttlingen, Germany, today announced the creation of a North America region that unifies its US, Canada, and Veterinary businesses under the leadership of Sonal Matai. Matai joined KARL STORZ in 2022 and was appointed to lead KARL STORZ United States in early 2024. As President of North America, Matai will now oversee key functions such as commercial operations, research and development,...

AventaMed, a KARL STORZ Company, Receives Expanded Indication for Solo+ Tympanostomy Tube Device (TTD)

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ United States is proud to announce that the US Food and Drug Administration (FDA) has cleared an expanded indication for the AventaMed Solo+™ Tympanostomy Tube Device (TTD), allowing its use in pediatric patients aged 6 months and older. This expanded clearance builds on the previous 510(k) clearance, which was indicated for patients 6 to 24 months old. The Solo+ device represents a significant advancement in pediatric ENT care. It is intended to...
Back to Newsroom